Cinda Biological Innovation 2.0

2021 is the 10th year of Cinda Biotech's establishment

On September 28, Cinda Biotech held an investor open day to portray the company's vision for the next ten years

The past 10 years: fruitful

Cinda Biotech started from scratch in 2011 and has harvested 4 biosimilar drugs and 1 original innovative drug on the market within ten years.

Innovent has continued to expand its product line through self-research and BD cooperation, and currently has 26 clinical stage products covering tumor and non-tumor fields

In terms of production, Cinda has built a leading antibody drug production base in the country, and is expected to build a 60,000-liter product line by the end of the year

Ten years will be called an era, but it is also a blink of an eye

The next 10 years: a hundred flowers bloom

In the next 2-3 years, Innovent is expected to market more than 10 products, IBI-348 (oribatinib), IBI376 (PI3Kδ inhibitor), IBI-310 (CTLA-4 inhibitor), IBI-306 (PCSK9 inhibitor), IBI-326 (BCMA CAR-T), IBI-344 (ROS1/NTRK inhibitor), etc.

Five years later, the next generation of immunotherapies represented by CD47, LAG3 and TIGIT will be based on solving the clinical needs of patients with PD-1 intolerance, non-response and relapse, and become a new engine for Cinda's development

After 10 years of developing into a leading company in the industry, Cinda Bio is becoming more and more attractive to talents

Focusing on the strategic goal of global innovation, Cinda National Cleansing Institute will become a powerful engine for Cinda Bio’s new drug discovery, and will focus on building antibody protein engineering technology and immunotherapy platforms, focusing on monoclonal antibodies, polyclonal antibodies, ADCs (including ADC ISAC), T /NK engager, Immuno-cytokine, Pro-drug and Polymeric IgG and other seven cutting-edge technology products

In just one year, the National Institute of Clearing Science has established more than 80 new drug research and development projects, and will achieve the launch of a number of world-first (First-in-Class) new drug products in the next 5-10 years

In 2021, Cinda Guoqing Institute has delivered 5 innovative products

In the field of antibody-conjugated drugs, Innovent has introduced antibody-conjugated technology through cooperation with companies such as Synaffix and Bolt Therapeutics, and deployed its product development platform

IBI343 is the first ADC product disclosed by Cinda.

In the field of antibodies, in addition to monoclonal antibodies and double antibodies, tertiary antibodies and polyclonal antibodies will also become Cinda's new drug layout considerations

IBI386 is a tertiary antibody product announced at the investment meeting.

IBI395 is a trispecific antibody developed on the basis of PD-1.
In addition to targeted inhibition of PD-1 to enhance T cell function, it can also increase CD8+ T cell proliferation
.
Preclinical data shows that IBI395 is well tolerated in cynomolgus monkeys, and it also shows anti-tumor activity in tumor models
.

T/NK cells and immune cytokines will also become Cinda's new layout areas
.
T/NK cell therapy improves tumor specificity and selectivity by redirecting cytotoxic T or NK cells to TME, and specifically kills tumor cells
.
At the same time, it can also be further armed with cytokines or costimulatory antibodies to enhance the efficacy
.
Immune cytokine therapy has powerful immune activation that can transform tumors from "cold tumors" to "hot tumors", expand and activate cytotoxic lymphocytes in TME, and reduce immune suppression to achieve a response to immunotherapy
.

IBI363 is an immune cytokine drug under development by Cinda
.
It can be seen from the data that IBI363 carries immune cytokine stimulation and PD-1 antibody function, which is similar to the effect mechanism of NKTR-214 by activating and expanding similar effects CD8+T and NK cells and other immune factors; the difference is that IBI363 While turning the tumor into heat, the PD-1 antibody also enhanced the function of T cells, achieving the killing of PD-1 resistant tumor cells
.
IBI363 is also well tolerated in cynomolgus monkeys, and induces significant tumor regression in tumor models at doses as low as 0.
03 mg/kg (ip.
QW), showing strong anti-tumor efficacy
.

In addition, Pro-body will also become the focus of Cinda
.
Probody therapy aims to more effectively target the treatment to the tumor by using the unique conditions of the tumor microenvironment.
It uses the high level of protease activity in the tumor microenvironment to cleave the substrate carried in the antibody and release the active antibody.
The cells are in an inactive state, reducing the toxicity of therapeutic drugs and expanding the therapeutic window
.

Cytomx has developed a number of prodrug immunotherapies using the Probody® platform
.
In addition to immune checkpoint antibody drugs (such as PD-1/L1, CTLA4), it has also been expanded to antibody drug conjugate drugs, T cell bispecific drugs, CAR-T and NK cell therapies
.

Of course, it is not difficult to see from the development projects of the National Institute of Clearance that Cinda will still focus on the expansion and development in the field of biological therapy, and biological drugs will still be Cinda’s important pipeline products
.
However, through diversified cooperation, including small molecule cooperation with Yasheng, Baoyuan and Jinfang, Cinda is also actively expanding the field of small molecule drugs
.
In the future, in the field of small molecules, Cinda will also develop PROTAC pipeline products
.
At the same time, it will also deploy AI technology, gene editing, mRNA, stem cell therapy and other cutting-edge technology fields
.

Concluding remarks

The development of an enterprise, no matter what kind of strategic planning and decision-making, ultimately depends on technology and products
.
In the next ten years, it is still unknown how high Cinda Biotech can achieve on the road of innovation 2.
0
.
However, it should be Cinda's only choice to uphold innovation and take an international path, breaking through the boundaries of science and providing life-changing drugs
.
With the enrichment of products, the addition of talents, the expansion of technology, and the integration of internationalization, Cinda Bio is expected to achieve more ambitious development, and the continuous development of high-quality biological drugs that the people can use will also be Cinda’s constant original intention.

.